Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10380 in Chinese Adults With Schizophrenia
NCT05964790Phase 2Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of obuprazine in schizophrenia, sponsored by Hansoh Pharmaceutical Group. Status: unknown.
02
Drugs
obuprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05964790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05964790.